Answers are grounded in this paper and cite their sources.
Observational study reveals elevated plasma and urinary IL-33 levels in MPO-ANCA glomerulonephritis, suggesting IL-33 serves as a biomarker for disease activity and active renal injury.
Myeloperoxidase (MPO)-ANCA–associated glomerulonephritis (MPO-AAGN) is a severe inflammatory kidney disease for which reliable biomarkers for disease activity assessment remains limited. We measured plasma and urinary interleukin-33 (IL-33) levels by ELISA in 80 MPO-AAGN patients and 20 healthy controls and evaluated their associations with the Birmingham Vasculitis Activity Score (BVAS), inflammatory markers, renal function indices, MPO-ANCA, and renal histopathology. IL-33 levels were higher in MPO-AAGN patients than in controls (plasma 393 ± 241, 230 ± 158 pg/mL, P = 0.0051; urine 500 ± 314, 277 ± 229 pg/mL, P = 0.0060). The plasma IL-33 concentration was correlated with the BVAS (ρ = 0.64; P < 0.001), remained independently associated with disease activity after multivariable adjustment, and improved the model performance beyond that of conventional clinical variables. Urinary IL-33 showed similar associations and were correlated with neutrophil-related indices. High IL-33 levels were associated with CD15⁺ neutrophil infiltration and active renal histopathological lesions, including fibrinoid necrosis and acute tubulointerstitial inflammation. Single-cell RNA sequencing suggested predominant endothelial IL-33 expression, suggesting that circulating and urinary IL-33 levels are associated with inflammatory activity and renal injury in MPO-AAGN patients and identifying IL-33 as a candidate biomarker associated with disease activity. Prospective multicenter studies are needed to establish its incremental clinical value beyond that of existing biomarkers.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: